tedalinab tedalinab tedalinab (grc-10693) is a drug developed by glenmark pharmaceuticals for the treatment of osteoarthritis and neuropathic pain, which acts as a potent and selective cannabinoid cb2 receptor agonist. it has a very high selectivity of 4700x for cb2 over the related cb1 receptor, has good oral bioavailability and has shown promising safety results and effective analgesic and antiinflammatory actions in early clinical trials. many related compounds are known, most of which also show high cb2 selectivity. tedalinabidentifiers iupac name (4s,7r)-1-(2,4-difluorophenyl)-n-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-4,7-methano-1h-indazole-3-carboxamide cas number916591-01-0pubchem cid24872953chemspider29340966unii5r7x34y6q1chemical and physical dataformulac19h21f2n3omolar mass345.394 g·mol−13d model (jsmol)interactive image smiles cc(c)(c)nc(=o)c1=nn(c2=c13cc2c3)c4=c(c=c(c=c4)f)f inchi inchi=1s/c19h21f2n3o/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11h,4-5,8h2,1-3h3,(h,22,25)/t10-,11+/m0/s1key:ntpzxhmtjgomcj-wdereuqcsa-n